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Abstract OBJECTIVE: Verify that resistance to aspirin may have an impact on pregnancy 
and neonatal outcome. 
METHODS: We enrolled 43 pregnant women, aged 30.7 ± 4.0 years regularly taking 
75 mg of aspirin daily and 32 (aged 30.8 ± 4 years) pregnant women not receiving 
aspirin who served as control group. Laboratory tests were performed at 18 to 22 
weeks of gestation, 28 to 32 weeks of gestation and 16 to 32 weeks after delivery. 
Resistance to aspirin was defined as urinary 11-dehydrothromboxane B2 (u11-
dTXB2) concentrations in the highest quartile and additionally, as the resistance 
index (RI) calculated for each woman, defined as the difference between u11-
dTXB2 concentration of each woman treated with aspirin and the median value at 
the same time point measured in the control group. 
RESULTS: Women taking aspirin in the highest quartile of u11-dTXB2 delivered 
prematurely (35.8±3.4 vs 38.1±1.7 weeks, p=0.02). Delivery of small for gesta-
tional age (SGA) newborns (p=0.003) as well as fetal distress (p=0.014) and 
preeclampsia (p=0.003) occured more frequently in aspirin-resistant women. 
Resistance to aspirin based on the RI value was also associated with higher preva-
lence of preeclampsia (p=0.02) and SGA newborns delivery (p=0.01). The two 
groups resistant to ASA designed on the basis of both (RI and u11—dTXB2 urine 
levels) methods compared with ASA sensitive group differed in frequency of SLE 
prevalence. 
CONCLUSION: Aspirin resistance may be associated with increased risk of adverse 
pregnancy outcomes including preeclampsia, premature delivery and delivery of 
SGA newborns.
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INTRODUCTION
Aspirin (ASA) reduces cardiovascular events risk by 
25% in a broad spectrum of patients with cardiovas-
cular diseases. Aspirin exerts its major antithrombotic 
effect by irreversibly acetylating platelet cyclooxygen-
ase-1 (COX-1), thereby inhibiting thromboxane A2 
(TXA2) synthesis (Antiplatelet Trialists’ Collaboration 
1994). A phenomenon termed aspirin resistance with a 
prevalence from below 1% to 45% of treated subjects has 
been postulated to be a potential cause of aspirin failure 
in the prevention of atherothrombosis (Pamukcu 2007). 
There is no widely accepted definition of aspirin resis-
tance. It is most commonly based on results of labora-
tory assays showing an insufficient inhibition of platelet 
function. Recent meta-analyses showed an association 
between laboratory aspirin resistance and poor clinical 
outcomes (Snoep et al. 2007; Krasopoulos et al. 2008). 
Aspirin resistance has been reported in up to 60% of 
patients after stroke or peripheral arterial disease, up 
to 70% in stable coronary heart disease and even up 
to 80% in acute myocardial infarction (Zimmermann 
& Hohlfeld 2008). Low dose aspirin is also prescribed 
to pregnant women, who suffer from antiphospholipid 
syndrome (APS) (Lim et al. 2007), underwent in vitro 
fertilization (IVF) (Waldenstrom et al. 2004) or are 
at high risk of preeclampsia and intrauterine growth 
restriction (IUGR) (Fayyad & Harrington 2005). To our 
knowledge aspirin resistance has not been investigated 
in pregnant women taking this medication. Therefore, 
the aim of this study was to evaluate the impact of aspirin 
resistance on pregnancy outcomes and newborn state. 
MATERIALS AND METHODS
Patients
The Ethics Committee of the Jagiellonian University 
approved this case-control study, and all patients gave 
informed written consent. We studied 75 pregnant 
women, aged 20 to 44 years. Forty-three women took 
75 mg of aspirin daily because of primary APS (n=18), 
secondary APS in the course of systemic lupus ery-
thematosus (SLE) (n=9), detected according to the 
American Rheumatism Association criteria (Tan et al. 
1982), high risk of preeclampsia (n=8), documented 
cardiovascular disease (n=5) and after IVF (n=3). The 
remaining 32 women, who were not treated with ASA, 
represented 24 healthy women and 8 women with SLE. 
APS was detected before pregnancy as described (Miya-
kis et al. 2006). Preeclampsia and hypertensive disorders 
were diagnosed on the basis of the American College 
of Obstetricians and Gynecologists (ACOG) criteria 
(ACOG practice bulletin 2002). Exclusion criteria were 
as follows: multiple pregnancy, current smoking, acute 
and chronic infections, intake of NSAIDs other than 
aspirin, platelet count < 100 × 103 /μl or > 400 × 103/μl, 
gastric ulcer, low albumin levels, aspirin allergy, bleed-
ing tendency, concomitant diseases such as cancer, dia-
betes mellitus, liver injury (alanine transaminase > 1.5 
times higher than the upper normal limit), renal failure 
(serum creatinine > 120 μmol/l), severe fetal malforma-
tions detected by ultrasound examination. All women 
treated with 75 mg of aspirin per day, have been taking 
the medication for at least 2 weeks before the first blood 
and urine collection until the end of the study. Women 
with SLE were treated with 4 mg methyloprednisolone 
before study enrollment. All patients were followed at 1 
month intervals during pregnancy and 16 to 32 (on aver-
age 26) weeks after delivery. At each follow-up, clinical 
outcomes were recorded and medication use, includ-
ing aspirin, was documented. Pregnancy outcome was 
recorded for each woman. We collected the following 
data: maternal age, maternal body mass index (BMI), 
gravidity, parity, gestational age at delivery, newborn 
birth weight, mode of delivery, occurrence of hyperten-
sion, preeclampsia, atherothrombotic events and post-
partum complications, such as hemorrhage. IUGR and 
small for gestational age (SGA) newborns were defined 
basing on the ACOG criteria. Venous blood and urine 
samples were obtained 3 times: between 18 and 22 weeks 
of gestation (2nd trimester), between 28 and 32 weeks 
of gestation (3rd trimester) and 16 to 32 (on average 26) 
weeks after delivery. In the ASA group venous blood 
and urine samples were obtained 3 times in 26 (66.7%) 
women, 2 times in 12 (30.7%) women and one time in 1 
(2.6%) woman. However, in the control group samples 
were obtained 3 times in 27 (87.1%) women, two times 
in 3 (9.7%) women and one time in 1 (3.2%) woman. 
Definition of aspirin resistance
To identify patients resistant to aspirin we determined 
urinary 11-dehydrothromboxane B2 (u11-dTXB2) 
(Cayman Chemical, USA ) concentrations and defined 
aspirin resistance based on the quartile distribution 
(the highest quartile – women resistant to aspirin) as 
described (Eikelboom et al. 2002). Moreover, a new 
parameter, the resistance index (RI), namely, the differ-
ence between u11-dTXB2 concentration of each woman 
treated with aspirin and the median value at the same 
time point measured in the control group.
Statistical Analysis
Results are expressed as mean value ± standard error 
of means (SEM) for continuous variables and as per-
centages for categorical variables. The W Shapiro-Wilk 
test was used to assess conformity with a normal dis-
tribution. When necessary, data were normalized using 
log transformation and were compared using Student’s 
t-test. For categorical variables the χ2 test was used. A 
p-value < 0.05 was considered statistically significant. 
RESULTS
The characteristics of the patient group and con-
trols are given in Tables 1 and 2. Women treated with 
aspirin had similar u11-dTXB2 during pregnancy 
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and after puerperium (Figure 1). However, they had 
lower u11-dTXB2 in comparison with the control 
group in the 2nd trimester (223.8 ± 257.1 pg/μmol cre-
atinine vs 499.6 ± 182.1 pg/μmol creatinine, p<0.0001), 
the 3rd trimester (232.6 ± 235 pg/μmol creatinine 
vs 677.9 ± 336.8 pg/μmol creatinine, p<0.0001) and 
after puerperium (170 ± 154 pg/μmol creatinine vs 
585.8 ± 186 pg/μmol creatinine; p<0.0001) (Figure 1). 
Quartile distribution
In the second trimester women in the lowest quartile 
had u11-dTXB2 below 49.5 pg/μmol creatinine, in the 
third trimester below 66 pg/μmol creatinine and after 
puerperium below 64.0 pg/μmol creatinine. Women 
in the highest quartile had u11-dTXB2 in the second 
trimester above 393 pg/μmol creatinine, in the third 
trimester above 411 pg/μmol creatinine and after puer-
perium above 258 pg/μmol creatinine. The lowest and 
the highest quartile groups differ with regard to u11-
dTXB2 in the 2nd trimester (52.6 ± 36.4 pg/μmol cre-
atinine vs 515 ± 241.2 pg/μmol creatinine; p=0.0004) 
as well as in the 3rd trimester (67 ± 26.1 pg/μmol cre-
atinine vs 537.6 ± 190 pg/μmol creatinine; p=0.0006) 
and after puerperium (138 ± 94.4 pg/μmol creatinine 
vs 228.5 ± 104 pg/μmol creatinine; p<0.0001). In the 
second trimester the lowest quartile comprised 9 
women but only 6 women stayed in this subgroup in 
the third trimester and only 4 women after puerperium. 
The lowest quartile comprised 9 women in the third 
trimester and 8 women after puerperium. The highest 
quartile consisted of 9 women, from whom 3 women 
delivered before the third trimester (33.3%), 5 women 
stayed in that quartile in the 3rd trimester and 2 women 
after puerperium. Using the range of values from the 
highest quartile in 2nd trimester women, there were 
9 women in 3rd trimester and 3 women in puerperium 
who have also qualified to the highest quartile. Preg-
nancy outcomes were analyzed women, who in the 2nd 
and/or 3rd trimester were classified to the lowest quar-
tile (women responsive to ASA, n=12) or to the highest 
quartile (women resistant to ASA n=13). There were 
significant differences with respect to SLE (p=0.01), 
the duration of the pregnancy (p=0.05), SGA newborn 
delivery (p=0.003) as well as preeclampsia and fetal dis-
tress occurrence (p=0.014) (Table 3). 
Resistance index
In the second trimester median u11-dTXB2 concentra-
tion in the control group was 426 pg/μmol creatinine, 
in the third trimester 552 pg/μmol creatinine and after 
puerperium 343 pg/μmol creatinine. After deducting 
the 2nd and 3rd trimester u11-dTXB2 values gathered 
from subjects in aspirin group from the median value in 
control group most women RI was below –200 (Figure 
2). The aspirin group was divided into a group of 
women with a significant suppression of TXB2 produc-
tion (women with good response to aspirin, n=20) and 
a group where that supression has failed (women with 
Tab. 1. Characteristics of women taking aspirin (ASA group) and 
controls.
Variables ASA group(n=43)
Control group
(n=32) p-value
Mean Maternal age 
(yr) 30.7 ± 4.3 30.8 ± 4 0.86
BMI (1), 
kg/m2 26.1 ± 5.2 23.1 ± 3.3 0.01
BMI (2), 
kg/m2 28.7 ± 5 25.4 ± 3.4 0.007
BMI (3), 
kg/m2 26.1 ± 4.6 23 ± 3.3 0.006
Primigravida, 
n (%) 5 (11.6) 18 (56.2) < 0.000
Primipara, 
n (%) 17 (39.5) 21 (65.6) 0.025
Among women who have been pregnant in the past
Previous stillbirths, 
n (%) 14 (32.6) 4 (12.5) 0.08
Previous miscarriages, 
n (%) 20 (46.5) 7 (21.9) 0.09
Previous premature 
delivery, n (%) 12 (27.9) 5 (15.6) 0.32
Previous hypertension in 
pregnancy, n (%) 15 (25.6) 3 (3.1) 0.02
Previous preeclampsia, 
n (%) 10 (23.3) 2 (6.2) 0.09
BMI-body mass index; (1) – second trimester; (2) – third trimester; 
(3) – after puerperium 
Tab. 2. Pregnancy outcomes in the aspirin-treated and control 
groups.
Variables ASA group(n=43)
Control group
(n=32) p-value
Mean duration of 
pregnancy (weeks) 34.8 ± 7.2 38.4 ± 2.4 0.004
Stillbirths, n (%) 4 (9.3) 1 (3.1) 0.55
Miscarriages, n (%) 4 (9.3) 1 (3.1) 0.55
Hypertension in 
pregnancy, n (%) 18 (41.9) 3 (9.4) 0.005
Preeclampsia, n (%) 11(25.6) 4 (12.5) 0.26
Mode of delivery
vaginal delivery n (%)
cesarean section n (%)
12 (27.9)
27 (62.8)
12 (37.5)
19 (59.4)
0.378
0.763
Atherothrombotic events 
during pregnancy, n (%) 4 (9.3) 0 (0) 0.076
Postpartum bleeding 
complications, n (%) 5 (11.6) 2 (6.2%) 0.428
Neonatal body weight at 
birth (gram) 2798 ± 982 3093 ± 559 0.42
Apgar score after 1 min ≤ 
7, n (%) 8 (18.6) 7 (21.8) 0. 726
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poor response to aspirin, n=16). Women from the high-
est quartile of u11-dTXB2 represented a group of poor 
response to aspirin, while those from the lowest quartile 
constituted a group of good response to aspirin, defined 
with the resistance index. In good responders the effect 
of aspirin seen as a reduction in u11-dTXB2 concentra-
tions during the second trimester was more profound 
during the third trimester and weaker after puerperium 
(Figure 2). In women who poorly responded to aspi-
rin, u11-dTXB2 concentrations increased during the 
third trimester, decreased after puerperium and then 
were similar to those in women responsive to aspirin 
(Figure 2). Furthermore, SLE (37.5% vs 5%, p=0.04), 
preeclampsia (50% vs 10%, p=0.02) and SGA newborns 
delivery (43.7% vs 5%, p=0.01) occurred more fre-
quently in women with poor response to ASA than in 
good responders to ASA. 
DISCUSSION
To our knowledge this study is the first to evaluate 
aspirin resistance in pregnant women. Importantly, 
aspirin resistance in pregnant women was associated 
with a higher risk of complications during pregnancy 
such as preeclampsia, preterm delivery and delivery of 
the SGA newborns. We also showed that pregnancy by 
itself favours this phenomenon. We also noted that ASA 
resistance occurs more frequently in pregnant women 
with SLE. 
In our study a mean concentration of u11-dTXB2 
was about 10 times higher than that observed by Eikel-
boom et al. (2002), in which elderly patients with car-
diovascular diseases were enrolled, and several times 
higher than that in a study of Vainio et al. (2004), where 
a radioimmunoassay was used to measure thrombox-
ane derivatives. However, current values were similar 
to those published by Qayyum et al. (2008), where non-
pregnant women were enrolled. 
Several studies showed that patients with aspirin 
resistance are at increased risk of cardiovascular dis-
orders and that the prevalence of this phenomenon is 
higher in women than in men (Chen et al. 2007; Lee et 
al. 2005). It might be speculated that aspirin resistance 
contributed to adverse pregnancy outcomes reported in 
the presented study.
During pregnancy, puerperium and breast feeding 
eicosanoids metabolism appears to be altered. There is 
evidence for increased expression of COX-1 and COX-2 
in pregnancy, and major production of thromboxane by 
trophoblast (Slater et al. 1994; Hirst et al. 1995; Luppi & 
Deloia 2006; Nelson & Walsh 1989). 
In our study women resistant to aspirin did not differ 
from good responders to aspirin with regard to age and 
BMI, i.e. the factors which may increase the risk of 
pregnancy complications (Duckitt & Harrington 2005). 
SLE occurred more frequently in poor responders to 
aspirin. Systemic lupus erythematosus is a known risk 
factor of poor obstetrical outcomes (Clowse et al. 2006). 
It is unclear which mechanisms underlie the associa-
tions between adverse pregnancy outcomes and aspirin 
resistance. It has been shown that some environmental 
and genetic factors contribute to low platelet response 
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Fig. 1. Distribution of urinary 11-dehydrothromboxane B2 (11-
dTXB2) concentrations in the aspirin (ASA) and control groups in 
the second (1) and third (2) trimester as well as after puerperium 
(3). *p<0.05 in comparison to the aspirin group
Fig. 2. Distribution of urinary 11-dehydrothromboxane B2 
concentrations in each subject in the aspirin group according to 
the resistance index in the second (1) and third (2) trimester as 
well as after puerperium (3).
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to aspirin. What is important is that even women who 
do not take ASA tend to have greater platelet activa-
tion, compared with men, in response to multiple ago-
nists. Moreover, after low-dose aspirin therapy women 
continue to have higher platelet aggregation compared 
to men, suggesting that women may benefit less from 
protective actions of aspirin (Becker et al. 2006). Undas 
et al. reported that aspirin resistance is associated with 
lack of aspirin-induced reduction in thrombin genera-
tion in response to vascular injury (Undas et al. 2007). 
It is tempting to speculate that heightened thrombin 
formation together with enhanced platelet reactivity 
present during pregnancy predispose to thrombosis 
in the placental vessels which might contribute to dis-
turbed intrauterine growth or preeclampsia (Sheu et al. 
2002).
Several limitations of the current study should be 
acknowledged. First, the number of women studied 
was limited and the women enrolled initially had high 
risk of obstetrical complications. A prospective trial 
involving a large number of women in reproductive 
age taking aspirin with the evaluation of resistance to 
the medication before conception and during preg-
nancy would allow to reliably assess the prevalence 
of this phenomenon in pregnant women. It should be 
emphasized that despite the fact that in this study the 
measures of aspirin resistance were not compared with 
those obtained for age-matched healthy non-pregnant 
women, but only with the data determined on average 
26 weeks after delivery, it seems that aspirin resistance 
is more pronounced during pregnancy than in the first 
year after delivery. Secondly, we cannot exclude that 
irregular aspirin intake could contribute to increased 
u11-dTXB2 concentration. Only witnessed intake of 
the drug or sample collection a few hours after aspirin 
administration is thought to ensure that non-adherence 
is not a reason for apparent aspirin resistance. We used 
a new approach to define aspirin resistance called the 
resistance index, which is aimed to objectively estimate 
aspirin’s effect in each subject referring to the concen-
tration of u11-dTXB2 in a group of women who were 
not treated with aspirin or other drugs.
Third, the optical aggregometry is nowadays con-
sidered to be the gold standard for determining aspi-
rin’s effect on platelet reactivity. We started our study 
in 2004 and decided to use the method introduced by 
Eikelboom et al. in 2002 to identify aspirin-resistant 
women. However, uncertain sensitivity and specific-
ity, low reproducibility are the major disadvantages of 
the currently used assays. Moreover, the correlations 
between results of different tests of aspirin respon-
siveness are poor (Santilli et al. 2009). Given the fact 
that aspirin inhibits mainly platelet TXA2 production, 
which can be determined by measuring urinary stable 
metabolites of TXA2 as in the present study, Eikelboom 
et al. reported that higher concentration of 11-dTXB2 
is associated with 1.8 fold higher risk of cardiovascular 
event despite aspirin treatment. However, the study of 
Santili et al. showed that among the biochemical and 
functional assays, serum TXB2 had the highest signal-
to-noise ratio and the lowest interindividual and intra-
individual variabilities. 
In conclusion, we addressed an intriguing issue of 
aspirin resistance in pregnant women for the first time. 
Our findings indicate that insufficient inhibition of 
COX-1 by aspirin in this group of patients might be 
clinically relevant and shows associations with adverse 
pregnancy outcomes. Furthermore, aspirin resistance 
was shown to be more frequent in women with SLE. 
Further studies in a larger group of pregnant women are 
needed to validate our results. Given increasing age of 
Tab. 3. Maternal characteristics in relation to quartile distribution 
based on urinary thromboxane B2 levels at the 2nd and 3rd 
trimester. 
Variables I quartile(n=12)
III quartile
(n=13) p-value
Mean Maternal age 
(yr) 30.2 ± 4.2 30 ± 4.5 0.85
BMI (1), 
kg/m2 27.3 ± 6.9 25.9 ± 3.8 0.5
BMI (2), 
kg/m2 30.2 ± 6.3 21.9 ± 13 0.06
BMI (3), 
kg/m2 27.2 ± 7 26.4 ± 3.3 0.72
Primigravida, 
n (%) 1 (8.3) 6 (46.1) 0.035
Primipara, 
n (%) 6 (50.0) 7 (53.8) 0.847
APS, 
n (%) 7(58.4) 8(61.5) 0.87
SLE,
n (%) 0 (0) 5(38.4) 0.016
Hypertension in pregnancy, 
n (%) 4(33.3) 7(53.8) 0.3
Preeclampsia, 
n (%) 0(0) 7(53.8) 0.003
Gestational diabetes, 
n (%) 1(8.3) 4(30.7) 0.35
Mean duration of 
pregnancy (weeks) 38.1±1.7 35.8±3.4 0.05
Mode of delivery
Cesarean section, n (%)
Vaginal delivery, n (%)
7(58.4)
5(41.6)
11(84.7)
2(15.3) 0.14
Neonatal body weight at 
birth (grams) 3145 ± 355 2467 ± 1180 0.06
SGA newborn delivery, 
n (%) 0(0.0) 7(53.8) 0.003
Apgar score after 1 min ≤ 
7, n (%) 1 (8.3) 7 (53.8) 0.014
BMI – body mass index; APS – antiphospholipid syndrome; SLE – 
systemic lupus erythematosus; SGA – small for gestational age
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pregnant women and higher prevalence of cardiovascu-
lar disorders in this population, the actual role of poor 
response to aspirin in pregnancy outcomes appears of 
vital clinical importance. 
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